Pathogenesis of Liver Fibrosis
The DOI matches its Crossref record; 220 of the 222 references it cites were found in a registry or an index, and 2 are not checked yet.
Abstract
Liver fibrosis is a major cause of morbidity and mortality worldwide due to chronic viral hepatitis and, more recently, from fatty liver disease associated with obesity. Hepatic stellate cell activation represents a critical event in fibrosis because these cells become the primary source of extracellular matrix in liver upon injury. Use of cell-culture and animal models has expanded our understanding of the mechanisms underlying stellate cell activation and has shed new light on genetic regulation, the contribution of immune signaling, and the potential reversibility of the disease. As pathways of fibrogenesis are increasingly clarified, the key challenge will be translating new advances into the development of antifibrotic therapies for patients with chronic liver disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“STAT3, a member of the STATs family, is a key transcriptional mediator of cellular processes [43, 44].”
From Saikosaponin b1 Attenuates Liver Fibrosis by Blocking STAT3/Gli1 Interaction and Inducing Gli1 Degradation (2025) · cites this paper as [43]
In the citing paper
“they may also derive from portal fibroblasts, bone marrow-derived cells, circulating fibrocytes, [7] and by the controversially discussed epithelial-tomesenchymal (EMT) [8,9] or endothelial-to-mesenchymal (EndoTM) transition.[10,11]”
From Nuclear receptors in liver fibrosis (2021) · cites this paper as [7]
Citations
Cites
The basics of epithelial-mesenchymal transition
Kalluri, R., & Weinberg, R. A. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39104 · Cited by 10,196
Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis
El–Serag, H. B., & Rudolph, K. L. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.061 · Cited by 5,415
Origins and Mechanisms of miRNAs and siRNAs
Carthew, R. W., & Sontheimer, E. J. (2009) · Cell · doi:10.1016/j.cell.2009.01.035 · Cited by 5,018
Kalluri, R., & Zeisberg, M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1877 · Cited by 4,538
Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver
Friedman, S. L. (2008) · Physiological Reviews · doi:10.1152/physrev.00013.2007 · Cited by 2,842
Self-citationMany roads to maturity: microRNA biogenesis pathways and their regulation
Winter, J., Jung, S., Keller, S., Gregory, R. I., & Diederichs, S. (2009) · Nature Cell Biology · doi:10.1038/ncb0309-228 · Cited by 2,656
Epithelial-mesenchymal transition and its implications for fibrosis
Kalluri, R., & Neilson, E. G. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200320530 · Cited by 2,649
Mechanisms of Hepatic Fibrogenesis
Friedman, S. L. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.003 · Cited by 2,634
Self-citationEndothelial-to-mesenchymal transition contributes to cardiac fibrosis
Zeisberg, E. M., Tarnavski, O., Zeisberg, M., Dorfman, A. L., McMullen, J. R., Gustafsson, E., Chandraker, A., Yuan, X., Pu, W. T., Roberts, A. B., et al. (2007) · Nature Medicine · doi:10.1038/nm1613 · Cited by 2,222
Bendelac, A., Savage, P. B., & Teyton, L. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141711 · Cited by 2,155
Research works printed but not linked: 15
- 10.1172/jci200112373 · DOI · Paper page
- 10.1055/s-2001-17556 · DOI · Paper page
- Stupack DG., 2007, Oncology, 21, 6
- Hehlgans S, 2007, Biochim. Biophys. Acta, 1775, 163
- Omenetti A, 2008, J. Clin. Investig., 118, 3331
- Pinzani M, 1996, Am. J. Pathol., 148, 785
- Sims DE., 1991, Can. J. Cardiol., 7, 431
- Thimgan MS, 1999, Am. J. Physiol., 277, G137
- 10.1136/gut.2005.088690 · DOI · Paper page
- Gao B., 2005, Cell Mol. Immunol., 2, 92
- Anania FA, 1995, Hepatology, 21, 1640
- Connolly MK, 2009, J. Clin. Investig., 119, 3213
- Seki E, 2009, J. Clin. Investig., 119, 1858
- McCrudden R, 2000, Histol. Histopathol., 15, 1159
- 10.1002/hep.23046 · DOI · Paper page
Cited by
Items 501–600 of 1,007
Saber, S., Goda, R. M., El‐Tanbouly, G. S., & Ezzat, D. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.09.021 · Cited by 43
Liu, D., Qin, H., Bi-xian, Y., Du, B., & Xue-lin, Y. (2020) · Drug Development Research · doi:10.1002/ddr.21649 · Cited by 43
Ji, K., Fan, M., Huang, D., Sun, L., Li, B., Xu, R., Zhang, J., Shao, X., & Chen, Y. (2022) · Biomaterials Science · doi:10.1039/d1bm01663f · Cited by 41
Prevention of rat liver fibrosis and carcinogenesis by coffee and caffeine
Furtado, K. S., Polettini, J., Dias, M. C., Rodrigues, M. A. M., & Barbisan, L. F. (2013) · Food and Chemical Toxicology · doi:10.1016/j.fct.2013.11.011 · Cited by 43
The feedback loop between miR-21, PDCD4 and AP-1 functions as a driving force for renal fibrogenesis
Sun, Q., Miao, J., Luo, J., Yuan, Q., Cao, H., Su, W., Zhou, Y., Jiang, L., Fang, L., Dai, C., et al. (2018) · Journal of Cell Science · doi:10.1242/jcs.202317 · Cited by 43
Chen, P., Huang, C., Meng, X., & Li, J. (2015) · Biochimie · doi:10.1016/j.biochi.2015.06.016 · Cited by 44
Li, H., Liu, T., Yang, Y., Cho, W. C. S., Flynn, R. J., Harandi, M. F., Song, H., Luo, X., & Zheng, Y. (2022) · Genes & Diseases · doi:10.1016/j.gendis.2022.08.013 · Cited by 42
Tang, B., Jin, C., Li, M., Liu, S., Zhang, X., Li, J., Ding, K., & Zang, Y. (2024) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2024.122826 · Cited by 42
Genetics and epigenetics in the fibrogenic evolution of chronic liver diseases
Zimmer, V., & Lammert, F. (2011) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2011.02.007 · Cited by 42
Cheng, Y., Tian, Y., Xia, J., Wu, X., Yang, Y., Li, X., Huang, C., Meng, X., Ma, T., & Li, J. (2017) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2017.01.005 · Cited by 42
“So far, several pathogenicmechanisms of hepatic fibrosis, including the innate immune cell contribution to the inflammatory and activation of liver resident myofibroblasts, has been identified (Popov and Schuppan, 2009; Hernandez-Gea and Friedman, 2011).”
BackgroundmiRNA-1271 inhibits cell proliferation in neuroglioma by targeting fibronectin 1
Gong, J., Wang, Z., & Liu, Z.-Y. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.6610 · Cited by 42
Chen, L., Huang, Y., Duan, Z., Huang, P.-Q., Yao, H., Zhou, Y., Ji, Q., & Liu, X. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.716209 · Cited by 42
Halofuginone for fibrosis, regeneration and cancer in the gastrointestinal tract
Pines, M. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i40.14778 · Cited by 42
Telocytes in Chronic Inflammatory and Fibrotic Diseases
Ibba‐Manneschi, L., Rosa, I., & Manetti, M. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-1061-3_4 · Cited by 42
Choi, Y. J., Kim, D. H., Kim, S. J., Kim, J., Jeong, S.-I., Chung, C. H., Yu, K.-Y., & Kim, S. Y. (2014) · Life Sciences · doi:10.1016/j.lfs.2014.05.012 · Cited by 41
Huang, Y., Fan, X., Tao, R., Song, Q., Wang, L., Zhang, H., Kong, H., & Huang, J. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26469 · Cited by 41
Engineered Relaxin as theranostic nanomedicine to diagnose and ameliorate liver cirrhosis
Nagórniewicz, B., Mardhian, D. F., Booijink, R. S., Storm, G., Prakash, J., & Bansal, R. (2019) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2018.12.008 · Cited by 41
Ju, B., Nie, Y., Yang, X., Wang, X., Li, F., Wang, M., Wang, C., & Zhang, H. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14210 · Cited by 41
The Significance of NOTCH Pathway in the Development of Fibrosis in Systemic Sclerosis
Zmorzyński, S., Styk, W., Filip, A. A., & Krasowska, D. (2019) · Annals of Dermatology · doi:10.5021/ad.2019.31.4.365 · Cited by 41
Elfeky, M. G., Mantawy, E. M., Gad, A. M., Fawzy, H. M., & El‐Demerdash, E. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.117096 · Cited by 41
Zhang, B., Lai, L., Tan, Y., Liang, Q., Bai, F., Mai, W., Huang, Q., & Ye, Y. (2020) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2020.112714 · Cited by 42
CGI-58: Versatile Regulator of Intracellular Lipid Droplet Homeostasis
Yu, L., Li, Y., Grisé, A., & Wang, H. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-6082-8_13 · Cited by 41
Zhu, H., He, C., Zhao, H., Jiang, W., Xu, S., Li, J., Ma, T., & Huang, C. (2020) · The FASEB Journal · doi:10.1096/fj.202000494rr · Cited by 41
Pan, Y. H., Wang, J., He, L., & Zhang, F. (2021) · Journal of Immunology Research · doi:10.1155/2021/6890423 · Cited by 41
“The pathway can be endogenously inhibited, which prevents the binding of smad2/3 to the receptor by smad6/7 [34].”
BackgroundIsoliquiritigenin alleviates the development of alcoholic liver fibrosis by inhibiting ANXA2
Liu, N., Liu, M., Jiang, M., Li, Z., Chen, W., Wang, W., Fu, X., Qi, M., Ali, M. H., Zou, N., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.114173 · Cited by 41
Hepatitis regulation by the inflammasome signaling pathway
Negash, A. A., & Gale, M. (2015) · Immunological Reviews · doi:10.1111/imr.12279 · Cited by 41
Bingül, İ., Aydın, A., Başaran‐Küçükgergin, C., Doğan‐Ekici, I., Çoban, J., Doğru‐Abbasoğlu, S., & Uysal, M. (2016) · International Immunopharmacology · doi:10.1016/j.intimp.2016.07.028 · Cited by 41
“HSCs increase the production of mainly type I and type III fibrillar collagen and are themajor cell type formatrix production in damaged liver tissue.”
BackgroundInfluentialWang, L., Yang, G., Li, Y., Yang, Y., Zhao, H., Ho, C., & Li, S. (2018) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.8b05179 · Cited by 41
Yadav, P., Singh, S. K., Rajput, S., Allawadhi, P., Khurana, A., Weiskirchen, R., & Navik, U. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108563 · Cited by 40
Wang, W., Li, A., Yan, B., Niu, S.-B., Tang, J., Li, X.-N., Du, X., Challis, G. L., Che, Y., Sun, H., et al. (2015) · Journal of Natural Products · doi:10.1021/acs.jnatprod.5b00814 · Cited by 40
Han, M., Liu, X., Liu, S., Su, G., Fan, X., Chen, J., Yuan, Q., & Xu, G. (2017) · Toxicology Letters · doi:10.1016/j.toxlet.2017.03.013 · Cited by 40
High-mobility group box 1 induces endoplasmic reticulum stress and activates hepatic stellate cells
He, Q., Fu, Y., Ding, X., Li, D., Wang, Z., Tian, D., & Yan, W. (2018) · Laboratory Investigation · doi:10.1038/s41374-018-0085-9 · Cited by 40
The Extra Virgin Olive Oil Polyphenol Oleocanthal Exerts Antifibrotic Effects in the Liver
Gabbia, D., Carpi, S., Sarcognato, S., Cannella, L., Colognesi, M., Scaffidi, M., Polini, B., Digiacomo, M., Salsano, J. E., Manera, C., et al. (2021) · Frontiers in Nutrition · doi:10.3389/fnut.2021.715183 · Cited by 40
“Thus, we evaluated OC ability in affecting MMP mRNA expression in LX2 cells, observing that MMP2, 3 and 7 were significantly reduced by OC treatment, whereas only a decreasing tendency could be observed for MMP9, probably due to the high variability observed in the experiments.”
BackgroundInfluentialTransient elastography for assessment of fibrosis in paediatric liver disease
Nobili, V., Monti, L., Alisi, A., Zupone, C. L., Pietrobattista, A., & Tomà, P. (2011) · Pediatric Radiology · doi:10.1007/s00247-011-2143-y · Cited by 41
Role of Smad3 in platelet-derived growth factor-C-induced liver fibrosis
Lee, J. I., Wright, J. H., Johnson, M. M., Bauer, R. L., Sorg, K., Yuen, S. Y., Hayes, B. J., Nguyen, L., Riehle, K. J., & Campbell, J. S. (2015) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00423.2014 · Cited by 40
Fibroscan improves the diagnosis sensitivity of liver fibrosis in patients with chronic hepatitis B
Huang, R.-G., Jiang, N., Yang, R.-D., Geng, X.-X., Lin, J.-M., Xu, G., Liu, D., CHEN, J., Zhou, G. F., WANG, S., et al. (2016) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2016.3135 · Cited by 40
Wu, X., Wang, Y., Wang, S., Xu, R., & Lv, X. (2017) · International Immunopharmacology · doi:10.1016/j.intimp.2016.12.017 · Cited by 40
Wang, B., Yang, H., Fan, Y., Yang, Y., Cao, W., Jia, Y., Cao, Y., Sun, K., Pang, Z., & Du, H. (2017) · Oncotarget · doi:10.18632/oncotarget.22539 · Cited by 40
Brg1 promotes liver fibrosis via activation of hepatic stellate cells
Li, H., Lan, J., Han, C., Guo, K., Wang, G., Hu, J., Gong, J., Luo, X., & Cao, Z. (2018) · Experimental Cell Research · doi:10.1016/j.yexcr.2018.02.003 · Cited by 40
DNA Methylation of PTGIS Enhances Hepatic Stellate Cells Activation and Liver Fibrogenesis
Pan, X., Yang, Y., Meng, H., Li, H.-D., Chen, X., Huang, H., Bu, F., Yu, H., Wang, Q., Huang, C., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00553 · Cited by 40
“The hepatic architecture will be disturbed by the prolonged and repeated accumulation of ECM proteins by which can form fibrotic scars and nodules, leading to hepatic dysfunction ultimately (Hernandez-Gea and Friedman, 2011; Trautwein et al., 2015).”
BackgroundPérez-Vargas, J., Zarco, N., Vergara, P., Shibayama, M., Segovia, J., Tsutsumi, V, & Muriel, P. (2016) · Human & Experimental Toxicology · doi:10.1177/0960327115578864 · Cited by 39
Zhang, K., Lin, L., Zhu, Y., Zhang, N., Zhou, M., & Li, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.894981 · Cited by 39
“Persistent hepatocyte damages, excessive ECM deposition, and abnormal proliferation of connective tissue in the liver can lead to liver fibrosis (Hernandez-Gea and Friedman, 2011).”
BackgroundMa, X., Zhou, W., Nie, Y., Jing, X., Li, S., Jin, C., Zhu, A., Su, J., Liao, W., & Ding, K. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.125540 · Cited by 39
Lan, T., Chen, B., Hu, X., Cao, J., Chen, S., Ding, X., Li, S., Fu, Y., Liu, H., Luo, D., et al. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.117516 · Cited by 40
Berberine Inhibition of Fibrogenesis in a Rat Model of Liver Fibrosis and in Hepatic Stellate Cells
Wang, N., Xu, Q., Tan, H. Y., Hong, M., Li, S., Yuen, M., & Feng, Y. (2016) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2016/8762345 · Cited by 39
Jin, K., Liu, Y., Shi, Y., Zhang, H., Sun, Y., Zhangyuan, G., Wang, F., Yu, W., Wang, J., Tao, X., et al. (2020) · Theranostics · doi:10.7150/thno.42658 · Cited by 39
Su, W. C., Tai, Y., Tang, S., Ye, Y., Zhao, C., Gao, J., Tuo, B., & Tang, C. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i28.4094 · Cited by 39
Dat, N. Q., Thuy, L. T. T., Hieu, V. N., Hai, H., Hoang, D. V., Thi Thanh Hai, N., Thuy, T. T. V., Komiya, T., Rombouts, K., Dong, M. P., et al. (2021) · Hepatology · doi:10.1002/hep.31752 · Cited by 35
Design of a highly potent GLP-1R and GCGR dual-agonist for recovering hepatic fibrosis
Song, N., Xu, H., Liu, J., Zhao, Q., Chen, H., Yan, Z., Yang, R., Luo, Z., Liu, Q., Ouyang, J., et al. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.12.016 · Cited by 39
Kaplow, I. M., Schäffer, D. E., Wirthlin, M. E., Lawler, A. J., Brown, A. R., Kleyman, M., & Pfenning, A. R. (2022) · BMC Genomics · doi:10.1186/s12864-022-08450-7 · Cited by 39
“This gene has been implicated in liver fibrosis [89–91], and a multi-species liver RNA-seq study found that it has higher expression in mouse liver relative to livers of other mammals and birds and lower expression in primate livers relative to livers of other mammals and birds [92].”
Backgroundp53 and Myofibroblast Apoptosis in Organ Fibrosis
McElhinney, K., Irnaten, M., & O'Brien, C. J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076737 · Cited by 39
Yu, Y., Sun, X., Gu, J., Yu, C. J., Wen, Y., Gao, Y., Xia, Q., & Kong, X. (2016) · International Journal of Biological Sciences · doi:10.7150/ijbs.15154 · Cited by 39
“Under persistent cycles of chronic liver injury and repair, the balance between extracellular matrix (ECM) synthesis and degradation is disrupted, which directly leads to the excessive accumulation of ECM, a typical characteristic of liver fibrosis [2].”
BackgroundLopez, O. N., Bohanon, F. J., Wang, X., Ye, N., Corsello, T., Rojas-Khalil, Y., Chen, H., Chen, H., Zhou, J., & Radhakrishnan, R. S. (2016) · RSC Advances · doi:10.1039/c6ra17459k · Cited by 39
Antioxidant axis Nrf2-keap1-ARE in inhibition of alcoholic liver fibrosis by IL-22
Ni, Y.-H., Huo, L., & Li, T. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i11.2002 · Cited by 39
Bae, M., Lee, Y., Park, Y., Shin, D., Joshi, P., Hong, S.-H., Alder, N. N., Koo, S. I., & Lee, J. (2019) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2019.06.001 · Cited by 39
“aHSCs are characterized by enhanced proliferation and migration, excessive secretion of ECM proteins, enhanced contractility, and increased production of growth factors and proinflammatory and pro-fibrogenic cytokines [3, 4, 6, 7].”
BackgroundKim, G., Kim, K. J., Rhee, Y., & Lim, S.-K. (2017) · PLoS ONE · doi:10.1371/journal.pone.0182202 · Cited by 38
Luo, S.-B., Luo, R., Huan-yuan, L., Zhang, R., Deng, G., Luo, H., Yu, X., Wang, C., Zhang, H., Zhang, Y., et al. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.111132 · Cited by 38
Huang, W., Peng, Y., & Kang, L. (2024) · View · doi:10.1002/viw.20240010 · Cited by 38
Immunopathogenesis of Hepatic Brucellosis
Giambartolomei, G. H., & Delpino, M. V. (2019) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2019.00423 · Cited by 39
“Quiescent HSC exert immunoregulatory roles secreting chemokines, chemokine receptors, macrophage inflammatory proteins (MIPs), and TLR and also function as antigen-presenting cells (Friedman, 2008; Hernandez-Gea and Friedman, 2011).”
BackgroundYang, L., Han, B., Zhang, M., Wang, Y., Tao, K., Zhu, M. X., He, K., Zhang, Z., & Hou, S. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00165 · Cited by 40
“However, HSCs become activated in response to a variety of profibrotic factors, such as transforming growth factor beta 1 (TGFβ1), that are generated during chronic liver injury, and exhibit phenotypes characterized by enhanced aortic smooth muscle actin (ACTA2) expression (Hernandez-Gea and Friedman, 2011; Tsuchida a…”
BackgroundXie, H., Xie, D., Zhang, J., Jin, W., Li, Y., Yao, J., Pan, Z., & Xie, D. (2020) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2020.08.014 · Cited by 38
Role of sphingosine 1-phosphate signalling in tissue fibrosis
Donati, C., Cencetti, F., Bernacchioni, C., Vannuzzi, V., & Bruni, P. (2020) · Cellular Signalling · doi:10.1016/j.cellsig.2020.109861 · Cited by 38
Zhou, Y., Chen, Y., Zhang, X., Xu, Q. R., Wu, Z., Cao, X., Shao, M., Shu, Y., Lv, T., Lu, C., et al. (2021) · Hepatology · doi:10.1002/hep.31780 · Cited by 38
Habibie, H., Adhyatmika, A., Schaafsma, D., & Melgert, B. N. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107941 · Cited by 38
Skin Fibrosis and Recovery Is Dependent on Wnt Activation via DPP4
Jussila, A. R., Zhang, B., Caves, E., Kirti, S., Steele, M., Hamburg‐Shields, E., Lydon, J. P., Yan, Y., Lafyatis, R., Rajagopalan, S., et al. (2021) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2021.10.025 · Cited by 39
Shu, G., Dai, C., Yusuf, A., Sun, H. M., & Deng, X. (2022) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2022.109039 · Cited by 38
Molina, M. F., Abdelnabi, M. N., Mazouz, S., Villafranca‐Baughman, D., Trinh, V. Q., Muhammad, S., Bédard, N., Laverde, D. O., Hassan, G. S., Polo, A. D., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.994480 · Cited by 38
“Indeed, our data also demonstrated upregulation of TGF-b frontiersin.org concomitantly with an activated state of HSCs.”
BackgroundJu, H., Han, K., Lee, J. D., & Ro, S. W. (2015) · International Journal of Cancer · doi:10.1002/ijc.29703 · Cited by 38
Epigenetic Modifications in Hepatic Stellate Cells Contribute to Liver Fibrosis
Zhao, Q., Qin, C., Zhao, Z., Fan, Y., & Wang, K. (2012) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.229.35 · Cited by 38
“…progression to cirrhosis may cause almost all kinds of hepatic complications, including portal hypertension, ascites, hepatic encephalopathy and impaired metabolic disturbance, therefore it is largely responsible for the mortality of hepatopathy (Mas et al. 2009; Hernandez-Gea and Friedman 2011).”
BackgroundCheng, C., & Pan, T. (2016) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.6b03700 · Cited by 38
El‐Sisi, A. E., Sokar, S. S., Shebl, A. M., & Mohamed, D. Z. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.03.013 · Cited by 38
Docosahexaenoic acid attenuates carbon tetrachloride-induced hepatic fibrosis in rats
He, J., Bai, K., Hong, B., Zhang, F., & Zheng, S. (2017) · International Immunopharmacology · doi:10.1016/j.intimp.2017.09.013 · Cited by 38
Circulating microRNAs as non-invasive biomarkers for hepatitis B virus liver fibrosis
Iacob, D. G., Roşca, A., & Ruță, S. M. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i11.1113 · Cited by 38
Time for Glucagon like peptide-1 receptor agonists treatment for patients with NAFLD?
Gastaldelli, A., & Marchesini, G. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.031 · Cited by 38
“As persistent inflammation precedes fibrosis [15], a reduced secretion of these pro-inflammatory factors might explain the positive effects of liraglutide on hepatic histology.”
BackgroundMa, J., Li, Y., Chen, M., Wang, W., Zhao, Q., He, B., Zhang, M., & Jiang, Y. (2023) · Cell Biology and Toxicology · doi:10.1007/s10565-022-09714-4 · Cited by 37
Dai, X., Du, Z., Jin, C., Tang, B., Chen, X., Jing, X., Shen, Y., He, F., Wang, S., Li, J., et al. (2023) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2023.121637 · Cited by 37
The extracellular matrix in inflammation and cancer
Zhang, W., Xiang, Y., Lu, C., Wang, F., Ren, H., Wu, H., & Yan, M. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00415-6 · Cited by 38
Zhang, W., Niu, M., Yan, K., Zhai, X., Zhou, Q., Zhang, L., & Zhou, Y. (2013) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2012.12.019 · Cited by 37
Hepatoprotective Principles and Other Chemical Constituents from the Mycelium of Phellinus linteus
Huang, S.-C., Wang, P.-W., Kuo, P., Hung, H., & Pan, T. (2018) · Molecules · doi:10.3390/molecules23071705 · Cited by 37
Kumar, S., Verma, A. K., Rani, R., Sharma, A., Wang, J., Shah, S. A., Behari, J., Gonzalez, R. S., Kohli, R., & Gandhi, C. R. (2020) · Hepatology · doi:10.1002/hep.31167 · Cited by 37
“(28) Thus, it was not surprising that HF/HC diet–fed ALR-H-KO mice progressed to cirrhosis, with very strong increases in TNFα and TGFβ.”
BackgroundInfluentialImpact of crosslink heterogeneity on extracellular matrix mechanics and remodeling
Mak, M. (2020) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2020.11.038 · Cited by 37
Ji, J., Feng, M., Huang, Y., & Niu, X. (2022) · Bioengineered · doi:10.1080/21655979.2022.2036902 · Cited by 37
“Activation of hepatic stellate cells is often the trigger of liver fibrosis [33,34].”
BackgroundPolanec, S. H., Bickel, H., Baltzer, P., Thurner, P., Gittler, F., Hodge, J. C., Bashir, M. R., & Ba‐Ssalamah, A. (2017) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.25657 · Cited by 37
Stem cell exosomes: new hope and future potential for relieving liver fibrosis
Li, L., Liu, Y., Wang, K., Mo, J., Weng, Z., Jiang, H., & Jin, C. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0854 · Cited by 37
Deep proteome profiling of metabolic dysfunction-associated steatotic liver disease
Pedersen, F. B., Akimov, V., Teuchler, M., Terkelsen, M. K., Wernberg, C. W., Larsen, F. T., Hallenborg, P., Lauridsen, M. M., Krag, A. A., Mandrup, S., et al. (2025) · Communications Medicine · doi:10.1038/s43856-025-00780-3 · Cited by 36
Fighting Liver Fibrosis with Naturally Occurring Antioxidants
Lin, L., Zhou, F., Shen, S., & Zhang, T. (2018) · Planta Medica · doi:10.1055/a-0757-0008 · Cited by 36
Yamato, M., Sakai, Y., Mochida, H., Kawaguchi, K., Takamura, M., Usui, S., Seki, A., Mizukoshi, E., Yamashita, T., Yamashita, T., et al. (2019) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.14647 · Cited by 36
Identification of Ppar γ -modulated miRNA hubs that target the fibrotic tumor microenvironment
Winkler, I., Bitter, C., Winkler, S., Weichenhan, D., Thavamani, A., Hengstler, J. G., Borkham‐Kamphorst, E., Kohlbacher, O., Plass, C., Geffers, R., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1909145117 · Cited by 36
“Activated HSCs (aHSCs) produce components of the ECM and growth factors, thus causing excessive ECM deposition, neoangiogenesis, and inflammation (6).”
BackgroundGuo, X., Li, Y., Wang, W., Wang, L., Hu, S., Xiao, X., Hu, C., Dai, Y., Zhang, Y., Li, Z., et al. (2022) · Phytotherapy Research · doi:10.1002/ptr.7569 · Cited by 36
“The occurrence of liver fibrosis is often thought to be related to the activation of hepatic stellate cells (HSCs) and the formation of fibrous scars (Hernandez-Gea & Friedman, 2011).”
BackgroundEfficiency of Hesperidin against Liver Fibrosis Induced by Bile Duct Ligation in Rats
Nasehi, Z., Kheiripour, N., Taheri, M. A., Ardjmand, A., Jozi, F., & Shahaboddin, M. E. (2023) · BioMed Research International · doi:10.1155/2023/5444301 · Cited by 36
“Chronic liver disease, due to secondary liver injury of any cause, leads to progressive LF, impairment of liver structure, vascular changes, and inappropriate reconstruction of liver tissue [3].”
BackgroundFusion protein of retinol‐binding protein and albumin domain III reduces liver fibrosis
Lee, H. S., Jeong, H., Park, S., Yoo, W., Choi, S., Choi, K., Lee, M., Lee, M., Cha, D.-R., Kim, Y., et al. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201404527 · Cited by 36
Pro- and Anti-fibrogenic Functions of Gram-Negative Bacterial Lipopolysaccharide in the Liver
Gandhi, C. R. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00130 · Cited by 36
“By down-regulating PDGFβR, LPS mitigates proliferation of aHSCs.”
BackgroundInfluentialZhang, N., Yao, H., Zhang, Z., Li, Z., Chen, X., Zhao, Y., Ju, R., He, J., Pan, H., Liu, X., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1131588 · Cited by 35
“Hepatic fibrosis is a reversible wound-healing response to liver injury, which is a major feature of any form of the chronic liver disease progressing to cirrhosis and liver failure (1).”
BackgroundWang, D., Zhang, C., Liu, H., Cui, Y., Li, X., Zhang, Z., & Zhang, Y. (2016) · International Journal of Nanomedicine · doi:10.2147/ijn.s101366 · Cited by 35
Lin, C., Adhikary, P., & Cheng, K. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.04.008 · Cited by 35
Wang, S., Tang, C. W., Zhao, H., Shen, P., Lin, C., Zhu, Y., & Han, D. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.656115 · Cited by 35
Zhang, X., Zhang, F., Kong, D., Wu, X., Lian, N., Chen, L., Lu, Y., & Zheng, S. (2014) · FEBS Journal · doi:10.1111/febs.12818 · Cited by 35
Churin, Y., Roderfeld, M., Stiefel, J., Würger, T., Schröder, D., Matono, T., Mollenkopf, H., Montalbano, R., Pompaiah, M., Reifenberg, K., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090608 · Cited by 35
Tao, Y., Wang, Q., Shen, L., Fu, W., & Liu, C. (2013) · Experimental Biology and Medicine · doi:10.1177/1535370213498979 · Cited by 35
Schattenberg, J. M., Nagel, M. C., Kim, Y. O., Kohl, T., Wörns, M., Zimmermann, T., Schad, A., Longerich, T., Schuppan, D., He, Y.-W., et al. (2012) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00525.2011 · Cited by 35
Metadata
- Authors
- Hernandez-Gea, V., & Friedman, S. L.
- Affiliations
- Division of Liver Diseases, Mount Sinai School of Medicine, New York, New York 10029;
- Icahn School of Medicine at Mount Sinai (US)
- ORCID
- Friedman, Scott L.
- Venue
- Annual Review of Pathology: Mechanisms of Disease
- Publisher
- Annual Reviews
- Published
- 2011-02-28
- Volume
- 6
- Issue
- 1
- Pages
- 425-456
- ISSN
- 1553-4006 (ISSN-L)
- 1553-4014
- OpenAlex
- W2142988890
- Cited by
- 1,809
- References
- 220
- Citations by year
- 2026: 81 · 2025: 123 · 2024: 121 · 2023: 112 · 2022: 148 · 2021: 174 · 2020: 145 · 2019: 119 · 2018: 117 · 2017: 131 · 2016: 136 · 2015: 124 · 2014: 97 · 2013: 76 · 2012: 67
- FWCI
- 10.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Annual Review of Pathology Mechanisms of Disease (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Keywords
- liver fibrosis, hepatic stellate cell activation, extracellular matrix, chronic viral hepatitis, hepatic steatosis, obesity, immune signaling, genetic control, fibrosis reversibility, antifibrotic therapy, chronic liver disease
- MeSH terms
- Humans, Liver, Liver Cirrhosis, Signal Transduction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.